Forty Seven is based out of Menlo Park. Forty Seven, Inc. operates as a clinical-stage immuno-oncology company. The Company develops novel checkpoint therapies to activate macrophages targeting cancer immune evasion pathways. Forty Seven serves customers in the State of California. The firm last filed a Form D notice of exempt offering of securities on 2017-10-31. The notice included securities offered of Equity
Contact Info
Contact information is taken directly from publicly disclosed SEC filings.
Forty Seven, Inc.1490 O'BRIEN DRIVE, SUITE A
MENLO PARK CA 94025
Business Phone: (650) 352-4150
SEC SIC CODE:
2834-PHARMACEUTICAL PREPARATIONS
2834-PHARMACEUTICAL PREPARATIONS
Recent SEC Filings
| Filing | Date |
|---|---|
| 15-12B | 2020-04-17 |
| SEC STAFF LETTER | 2020-03-05 |
| SEC STAFF LETTER | 2020-02-06 |
| SC 13G/A | 2020-04-09 |
| EFFECT | 2020-04-07 |
| 4 | 2020-04-07 |
| 4 | 2020-04-07 |
| 4 | 2020-04-07 |
| 4 | 2020-04-07 |
| 4 | 2020-04-07 |